Nucleic Acid Amplification Test Market: New Era of Diagnostics

Increasing efforts by governments and healthcare agencies to limit the spread of infectious diseases through awareness programs and routine checkup camps. These efforts are resulting in relatively reduced spread of infections. However, usage of NAAT is rapidly increasing with these awareness programs and routine checkup camps. In addition, epidemic outburst, such as the recent one by the Zika virus, has a positive effect on the development of diagnostic screening and treatment methods for infectious disease.

Over a period, a large number of disease-specific diagnostic tests have been developed, such as ELISA for HIV and Pap smear for cervical cancer. However, these tests have limitations like ability to detect only after a particular time of infection or initiation of the disease, longer procedural time, and requirement of a large amount of reagents. The introduction of advanced NAT enabled minimizing the turnaround time for diagnosis, to gain more accurate results that would ultimately help in designing of effective therapies.

Global Nucleic Acid Amplification Test Market, by Region, 2015

The highest usage of NAAT is in blood screening procedures where it is now possible to conduct a single test for screening multiple infectious agents instead of disease-specific tests. This is expected to help in reducing the prices of the blood and blood products. In addition, the tests are used as early detection technique for many viruses, including herpes simplex virus and cytomegalovirus, as well as viruses causing respiratory diseases.

Many companies in Europe and North America focus on biotechnology. Availability of ample funds and presence of a large target population are the reasons behind the faster evolution of biotechnology in these regions. NAAT is among the fastest growing segments in the diagnostic biotechnology.

Governments encouraging entry of international players is anticipated to be augment the growth of Asia Pacific. Thus, the region is expected to show the fastest growth from 2016 to 2025, due to presence of fast growing economies and favourable demographics, such as high prevalence of infectious diseases, and rising adoption of the advanced diagnostic technologies. The government initiatives to implement NAT in the public health services is anticipated to create growth opportunities in the region.

There are currently a few major players that decide the market dynamics. Patent expiration and increasing number of investors are expected to flourish the local market and ultimately raise the level of competition.Some of the major players operating in this sector include F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Beckman Coulter, Inc.; Abbott Laboratories, Inc.; Illumina, Inc.; Siemens Healthineers; bioMérieux SA; Novartis AG; and Bio-Rad Laboratories, Inc.

  In-depth report on global nucleic acid amplification test market by Grand View Research:

http://www.grandviewresearch.com/industry-analysis/nucleic-acid-amplification-testing-naat-market